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Abstract
The protective role of Sirt1 in renal damage was investigated. Sirt1 in proximal tubules (PT) was
downregulated before albuminuria occurred in streptozotocin-induced or obese-type (db/db)
diabetic mice. PT-specific Sirt1 transgenic (TG) and knockout (KO) mice showed prevention and
aggravation of the glomerular changes occurring in diabetes, respectively, and non-diabetic KO
mice exhibited albuminuria, suggesting that Sirt1 in PT affects glomerular function.
Downregulation of Sirt1 and upregulation of the tight junction protein Claudin-1 by Sirt1-
mediated epigenetic regulation in podocytes contributed to albuminuria. These phenomena were
not observed in 5/6 nephrectomized mice. We also demonstrated retrograde interplay from PT to
glomeruli using nicotinamide mononucleotide (NMN) from conditioned medium, measurement of
the auto-fluorescence of photoactivatable NMN, and injection of fluorescence-labeled NMN. In
human subjects with diabetes, Sirt1 and Claudin-1 levels were correlated with proteinuria level.
Sirt1 in PT protects against albuminuria in diabetes through maintaining NMN concentrations
around glomeruli and controlling podocyte function.
INTRODUCTION
Diabetic nephropathy is the most common cause of end-stage renal disease, affecting about
one-third of subjects with diabetes mellitus1. Early diabetic nephropathy is characterized by
mesangial hypertrophy and glomerular hyperfiltration with microalbuminuria. Sir2 is a
nicotinamide adenine dinucleotide (NAD)-dependent protein deacetylase and a member of
the sirtuin class of proteins. Sirt1, a mammalian ortholog of Sir2, deacetylates histones and
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various transcription factors, protecting against acute and chronic stress2,3. Sirt1 mitigates
diabetes by attenuating hepatic insulin resistance4,5 and enhancing pancreatic insulin
secretion6. Recently, the renal protective effects of Sirt17,8 and a pathogenic role for Sirt1 in
diabetic nephropathy9–12 have been reported, although the relationship between renal Sirt1
and the pathogenesis of kidney damage in diabetes have not been investigated.
Our group recently produced transgenic (TG) mice overexpressing Sirt1 specifically in the
proximal tubules (PT) and reported that Sirt1 alleviated acute kidney injury13,14. In diabetic
nephropathy, PT changes are evident even in the early stages15. PT changes are reportedly
closely linked to the loss of renal function and more accurately predict the progression of
diabetic nephropathy than glomerular changes15. Therefore, our TG mice are good models
for exploring the PT-specific role of Sirt1 in diabetic nephropathy. We used these mice as
well as PT-specific Sirt1 knock-out mice to investigate the protective role of Sirt1 in
diabetes-induced albuminuria.
RESULTS
Sirt1 in diabetes and effects of Sirt1 overexpression
Downregulation of Sirt1 expression in a diabetic milieu or high glucose condition has been
reported in various cells16,17. We examined Sirt1 expression in PT and glomeruli after
streptozotocin (STZ) treatment. By immunostaining, we detected Sirt1 expression in both
PT and glomeruli before STZ treatment. Eight weeks after STZ treatment, Sirt1 levels were
decreased in PTs but remained unchanged in glomeruli. Twenty-four weeks after STZ
treatment, Sirt1 levels in glomeruli were also decreased (Fig. 1a). Laser micro-dissection
followed by RT-PCR revealed that Sirt1 mRNA expression decreased in PT before
glomeruli in diabetic mice (Fig. 1b, Supplementary Fig. 1a,b). These observations indicated
that molecular alterations in PT occurred at a very early stage in diabetes before the increase
in albuminuria, as documented in several previous reports18–20. To delineate the significance
of this change in PT, we examined the effects of Sirt1 overexpression in PT-specific Sirt1
transgenic (TG) mice. First, we confirmed using an antibody to FLAG that TG mice
overexpressed Sirt1 in PT, but not in glomeruli (Supplementary Fig. 1c). Immunoblotting,
immunostaining and laser micro-dissection followed by RT-PCR all showed that the
reduction in Sirt1 expression in wild-type (WT) mice at 24 weeks after STZ treatment was
prevented in TG mice, in PTs and glomeruli, (Fig. 1c and Supplementary Fig. 1a,b). Plasma
glucose concentrations increased in STZ-treated diabetic mice 4 weeks after treatment, in
both WT and TG mice, and the increase was sustained until 24 weeks. We sacrificed mice
24 weeks after STZ treatment Supplementary Fig. 1d). Plasma glucose concentrations did
not differ between WT and TG mice, at either 8 or 24 weeks (Supplementary Fig. 1d). Body
weights, blood urea nitrogen and creatinine concentrations, creatinine clearance, and kidney
weights did not differ between WT and TG mice Supplementary Fig. 1e–i). Eight weeks
after STZ treatment, urinary albumin excretion was unchanged (Fig. 1d), although 24 weeks
after treatment, urinary albumin excretion was greater in WT mice treated with STZ (WT
+STZ) than in those treated with saline (Fig. 1d). This difference was less pronounced in TG
mice treated with STZ (TG+STZ, Fig. 1d). Mesangial matrix accumulations were not
different between WT+STZ and TG+STZ mice (Supplementary Fig. 1j). By electron
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microscopy (EM), the density of tight pores was not affected by STZ at 8 weeks (Fig. 1e),
although WT mice treated with STZ showed higher tight pore densities than WT mice
treated with saline at 24 weeks. This difference was less pronounced in TG+STZ mice (Fig.
1e).
Sirt1-dependent upregulation of Claudin-1 expression
To elucidate the molecular mechanisms underlying the amelioration of albuminuria by PT
Sirt1 overexpression, we performed DNA microarray analysis using micro-dissected
glomerular regions to examine differences in gene expression between WT+STZ and TG
+STZ mice. In the Welch t-test with a cutoff of P < 0.05, 26 genes showed a statistically
significant upregulation greater than 4-fold in TG mice (Supplementary Table 1) and 29
genes showed downregulation in TG mice to ≤25% of the level in WT mice (Supplementary
Table 2). We selected four upregulated genes and four downregulated genes for which the
functions were known and confirmed the differential expression of these genes by
quantitative real-time RT-PCR using whole kidney samples (Supplementary Fig. 2). Only
Claudin-1 showed a significant reduction in mRNA level in STZ+TG mice compared with
STZ+WT mice. In addition, among the eight genes, Claudin-1 was reported to be the most
related to the pathogenesis of albuminuria21,22. Therefore, we focused on the changes in
Claudin-1 expression.
Expression of Claudin-1 mRNA, a putative parietal epithelial cell (PEC)-specific
marker23–25, was higher in WT+STZ mice than in saline-treated WT mice (WT+Sal). This
difference was not seen in TG mice (Fig. 1f). By microarray analysis, no other isoforms of
Claudin were upregulated or downregulated. By immunostaining, Claudin-1 appeared to be
expressed only in PECs in WT+Sal mice (Fig. 1g). Claudin-1 levels were higher in WT
+STZ mice than in WT+Sal mice, and Claudin-1 extended ectopically in podocytes (Fig.
1g). This difference in Claudin-1 levels in both PECs and podocytes was not seen in TG
mice (Fig. 1g). Laser micro-dissection followed by real-time PCR revealed lower levels of
Sirt1 mRNA expression in PECs and PT cells of WT+STZ mice than in those of WT+Sal
mice (Fig. 1h). Claudin-1 mRNA expression was substantially higher in PECs of WT+STZ
mice compared with those of WT+Sal mice, although we detected little Claudin-1
expression in PT cells of WT+Sal and WT+STZ mice (Fig. 1h). In TG mice, Sirt1 mRNA
expression levels were unaffected by STZ in either PT or PECs (Fig. 1i). We detected little
expression of Claudin-1 in PT and PECs, and its expression in these regions was unaffected
by STZ (Fig. 1i). Finally, in immunogold EM of the foot processes of podocytes, we did not
observe gold particles for Claudin-1 in WT+Sal mice, while we observed large numbers in
WT+STZ mice. This difference was not seen in TG mice (Supplementary Fig. 3a–c).
Collectively, these findings suggested that Sirt1 overexpression in PT altered Claudin-1
expression in PECs as well as in podocytes, but not in PT cells.
Effects of Claudin-1 expression in podocytes
To examine the effects of Claudin-1 on albuminuria, we transferred a construct containing
the Claudin-1 gene inserted downstream of a podocyte-specific promoter, a 2.5-kb fragment
of the NPHS2 (podocin) promoter, into WT mice with the aid of a hemagglutinating virus of
Japan envelope vector26. Injection of the Claudin-1 gene driven by a Podocin promoter
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successfully upregulated Claudin-1 expression in podocytes (Fig. 2a). This gene transfer
induced albuminuria in WT mice and aggravated albuminuria in STZ-treated mice (Fig. 2b).
These effects were accompanied by greater podocyte effacement (Fig. 2c).
The β-catenin/Snail pathway plays a role in the pathogenesis of albuminuria27, and
Claudin-1 reportedly activates the β-catenin/Snail pathway in colon epithelial cells28. Thus,
we examined whether Claudin-1 activated the β-catenin/Snail pathway in podocytes.
Transfer of Claudin-1 gene upregulated both β-catenin and Snail mRNA levels
concomitantly with downregulation of the mRNAs for the slit membrane protein Podocin
and the actin-binding protein Synaptopodin in micro-dissected glomeruli (Fig. 2d).
Overexpression of Claudin-1 was also associated with increased expression of β-catenin and
Snail, and downregulated synaptopodin expression in cultured podocytes (Fig. 2e).
Collectively, these findings suggest that Claudin-1 expression in podocytes induced
podocyte effacement and led to albuminuria, presumably through the activation of β-catenin/
Snail signaling.
Deficiency of Sirt1 in proximal tubules causes albuminuria
To confirm the role of PT Sirt1 in albuminuria in diabetes, we also created PT-specific
Sirt1-deficient mice (conditional knockout mice, CKO) by crossing Sirt1flox/flox mice on a
C57BL/6J background with γGT-Cre mice. CKO mice showed specific loss of Sirt1
expression in the kidney (Fig. 2f). Immunofluorescence staining revealed that control
littermates aged 8 weeks expressed Sirt1 in the glomeruli and tubules in kidney tissues. In
CKO mice, we observed almost complete elimination of Sirt1 expression in tubules,
whereas glomerular expression was unaffected, denoting a tubular-specific knockout of Sirt1
(Supplementary Fig. 4a).
We then compared phenotypes in 32-week-old mice (24 weeks after saline or STZ
treatment). Micro-dissection followed by real-time PCR revealed lower PT Sirt1 expression
levels in CKO mice than in control mice (Fig. 2g, Cont+Saline vs. CKO+Saline). Of note,
levels in glomeruli were also lower (Fig. 2g, Cont+Saline vs. CKO+Saline). Sirt1 expression
levels in PTs and glomeruli were also lower in control mice treated with STZ (Cont+STZ)
and CKO mice treated with saline (CKO+Saline) than in control mice treated with saline
(Cont+Saline). This difference was more prominent in CKO mice treated with STZ (CKO
+STZ) (Fig. 2g). The results of immunofluorescence staining (Supplementary Fig. 4a) were
consistent with those of real-time PCR. By EM, the density of tight pores was higher in Cont
+STZ and CKO+Saline mice than in Cont+Saline mice. An even higher tight pore density
was seen in CKO+STZ mice (Fig. 2h). Immunostaining (Fig. 2i), real-time PCR after laser
micro-dissection (Fig. 2i), and immunogold electron microscopy (Supplementary Fig. 4b)
revealed higher levels of Claudin-1 expression in Cont+STZ and CKO+Saline mice
compared with Cont+Saline mice, an effect that was further enhanced in CKO+STZ mice.
Urinary albumin excretion was greater in Cont+STZ and CKO+Saline mice than in Cont
+Saline mice, and higher again in CKO+ STZ mice (Fig. 2j). These data from PT-specific
Sirt1-deficient mice confirmed the pivotal role of endogenous PT Sirt1 in maintaining
glomerular structure and function during the initiation of albuminuria in diabetes as well as
in the normal condition.
Hasegawa et al. Page 4
Nat Med. Author manuscript; available in PMC 2014 June 02.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sirt1 overexpression in obese and nephrectomized mice
We further investigated the effects of Sirt1 overexpression in PT in another diabetic model
and 5/6 nephrectomized (5/6Nx) mice. We crossed our Sirt1 TG mice with obese db/db mice
and produced Sirt1 TG-db/db mice (TG-db/db). Plasma glucose concentrations and body
weights were significantly greater in WT-db/db mice (WT-db/db) and TG-db/db mice than
in nondiabetic (ND) mice. Plasma glucose concentrations were already elevated at 8 weeks
of age, and this elevation was sustained until 32 weeks of age (Supplementary Fig. 4c).
Body weights, blood urea nitrogen and creatinine concentrations, creatinine clearance, and
kidney/body weight ratios did not differ between WT-db/db and TG-db/db groups
(Supplementary Fig. 4d–h). Sirt1 expression in WT-db/db mice was lower than that in WT-
ND mice, but there was no significant difference in Sirt1 expression levels between TG-ND
mice and TG-db/db mice (Fig. 3a). Urinary albumin excretion, Claudin-1 levels, and the
density of tight pores did not differ between 32-week-old TG-ND mice and WT-ND mice.
However, these parameters were greater in WT-db/db mice than in either type of ND mice at
32 weeks of age when glomerular lesions were evident. In TG-db/db mice, no such
difference was observed (Fig. 3b–d). PAS staining revealed an increase in mesangial matrix
accumulation in diabetic groups, but there was no difference between WT-db/db and TG-
db/db mice (Supplementary Fig. 4i).
To explore the role of renal tubular Sirt1 in non-diabetes-related albuminuria, we performed
similar experiments using 5/6Nx mice29. Twenty-four weeks after nephrectomy, the
expression of Sirt1 was unchanged, and PT-specific Sirt1 TG mice expressed high levels of
Sirt1 in the kidney (Fig. 3e). The 5/6Nx mice exhibited albuminuria to a level that was
similar to that in STZ-treated mice. However, PT-specific Sirt1 overexpression could not
prevent albuminuria in 5/6Nx mice (Fig. 3f). Collectively, these data indicated that the effect
of PT Sirt1 in preventing albuminuria is a diabetes-specific event.
Epigenetic mechanism of Sirt1-induced Claudin-1 upregulation
We further explored the mechanism regulating Claudin-1 expression using human-derived
renal epithelial (HRE) cells because this cell line expresses Claudin-1 and has a similar
phenotype to that of PECs. Sirt1 expression decreased and Claudin-1 expression increased
as the glucose concentration increased (Fig. 4a). Transfection of cells with an increased
amount of Sirt1 expression vectors resulted in downregulation of Claudin-1 expression (Fig.
4b). Sirt1 overexpression blunted the upregulation of Claudin-1 by glucose (Fig. 4b). We
investigated the epigenetic mechanisms for regulating Claudin-1 expression30. A computer
search indicated that CpG islands, a target for methylation, reside within the Claudin-1
genes of both mice and humans (Fig. 4c). Methylation analysis revealed that the amount of
methylated CpG decreased with increasing glucose concentration in concert with the
upregulation of Claudin-1 (Fig. 4d). The transfection of cells with increased concentrations
of Sirt1 expression vectors induced hypermethylation of the Claudin-1 gene in concert with
the downregulation of Claudin-1 (Fig. 4 d). Transfection of cells with an siRNA for Sirt1
induced hypomethylation of the Claudin-1 gene and upregulated Claudin-1 expression (Fig.
4e). Sirt1 overexpression blunted the hypomethylation of Claudin-1 gene CpG islands
induced by glucose (Fig. 4f).
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Treatment of cells with 5-aza-dC, a DNA methyltransferase (Dnmt) inhibitor, reduced the
level of methylation of the Claudin-1 gene and increased Claudin-1 protein levels (Fig. 4g).
The methylation of the Claudin-1 CpG region induced by overexpression of Sirt1 was
suppressed by co-transfection of cells with an siRNA for Dnmt1 (Fig. 4h), but not by co-
transfection of cells with siRNAs for Dnmt3a and Dnmt3b (Supplementary Fig. 5a,b). In an
inactivation model of gene expression, histone deacetylation induces histone methylation,
which leads to the recruitment of Dnmt31,32. We examined chromatin modification status by
chromatin immunoprecipitation (ChIP) assays to confirm the molecular events in the CpG
islands in the Claudin-1 gene33,34. Acetylation of both H3 and H4 histones was greater in
both CpG and non-CpG regions in cells treated with sirtinol, a Sirt1 inhibitor, than in control
cells (Fig. 4i). Histone H3K9 dimethylation in the CpG region was decreased by sirtinol,
although histone H4K20 dimethylation was unaffected by sirtinol treatment (Fig. 4i). These
results suggested that Sirt1 deacetylated H3 and H4 histones in both CpG and non-CpG
regions and enhanced dimethylation of H3K9 in CpG regions (Fig. 4i). They also indicated
that Claudin-1 expression was regulated epigenetically through deacetylation of histone H3
and H4 by Sirt1, with subsequent CpG methylation of the Claudin-1 gene by recruited
Dnmt1.
We confirmed these epigenetic changes in PECs micro-dissected from STZ-treated Sirt1 TG
mice. Diabetes-induced hypomethylation of Claudin-1 CpG regions and Sirt1
overexpression led to higher levels of methylation of these regions (Fig. 4j). In parallel with
these epigenetic changes, the levels of Claudin-1 mRNA expression were higher in WT
+STZ mice than in TG+STZ mice (Fig. 4j). We obtained more quantitative results by
bisulfite sequencing using micro-dissected PECs (Supplementary Fig. 5c,d).
Interaction between PT cells and podocytes through nicotinamide mononucleotide
Our data indicated that the phenotype changes in PT cells affected contiguous cells
including podocytes. We examined this interaction between PT cells and podocytes in
conditioned medium (CM) experiments. We transfected a human renal PT cell line, HK-2
cells, cultured either in normal (NG) or high glucose (HG) conditions, with Sirt1 expression
vectors (Fig. 5a). We obtained CM from these cells and treated podocytes with or without
these conditioned media. Podocytes cultured without CM expressed Sirt1 protein but had
undetectable levels of Claudin-1 protein. In the absence of CM, HG culture conditions did
not change the levels of these molecules. However, CM from HK-2 cells cultured in NG
conditions induced higher levels of Sirt1 expression in podocytes. Exposure of podocytes to
CM from HK-2 cells cultured in HG conditions (HG+Cont) downregulated Sirt1 and
upregulated Claudin-1 in podocytes. These effects were diminished in podocytes exposed to
CM from HK-2 cells transfected with Sirt1 expression vector and cultured in HG conditions
(Fig. 5b). Thus, CM from HK2 cells contained some factor responsible for the Sirt1
expression alteration in podocytes.
Nicotinic acid metabolites are candidates for this effect because they are related to Sirt1
expression35 and activity36,37. In this metabolic pathway, nicotinamide (NAM) is converted
into nicotinamide mononucleotide (NMN) by intracellular-type NAM
phosphoribosyltransferase (iNAMPT). NMN is further converted into NAD by nicotinamide
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mononucleotide adenylyl transferase (NMNAT). NAD is then converted by Sirt1 into NAM,
forming a metabolic loop36,38. In our culture system, NMN concentrations and the NAD/
NADH ratio were lower in CM from HK-2 cells cultured in the HG condition than in CM
from HK-2 cells cultured in the NG condition. We did not observe such a difference in CM
from Sirt1-transfected HK-2 cells (Fig. 5c). Exogenous supplementation of NMN into CM
from HK-2 cells cultured in the HG condition induced higher levels of Sirt1 and lower levels
of Claudin-1 in podocytes. Sirtinol abrogated these effects of NMN treatment (Fig. 5d). We
did not observe these molecular changes when we used mannitol in the place of glucose,
indicating that osmotic changes had no effects (Supplementary Fig. 6a–f. For details, see
Supplementary Results). Collectively, these findings suggested that Sirt1 prevented the HG-
induced decrease in NMN and NAD concentrations in CM, which could, at least in part,
have contributed to the changes in Sirt1 expression and probably the subsequent alteration of
Claudin-1 expression in podocytes. We measured NMN concentrations inside the cells in
CM experiments. NMN photoactivated by pretreatment with perchloric acid and
acetophenone at high temperature39 was detected in HK-2 cells (Fig. 5e). HK-2 cells
cultured in HG contained lower concentrations of NMN than did those cultured in NG (Fig.
5e). This difference was reversed in HK-2 cells transfected with the Sirt1 expression vector.
In podocytes, basal concentrations of NMN were almost undetectable (Fig. 5e). One and 2 h
after exposure to normal glucose CM, NMN concentrations inside podocytes were higher.
The NMN concentration was low when we treated podocytes with high glucose CM, but
was higher in podocytes treated with CM from Sirt1-transfected HK-2 cells (Fig. 5e). These
data indicated that NMN synthesized and secreted by HK-2 cells was taken up by podocytes.
Next, we directly measured tissue NMN concentrations in kidneys using this method. We
detected NMN mainly in tubular regions (Fig. 5f), probably because of the high expression
levels of the NMN-producing enzyme iNampt (Fig. 5g). NMN levels were lower in WT
mice treated with STZ than in WT mice treated with saline (Sal), and this difference was
less apparent in Sirt1 TG mice (Fig. 5f). Consistently, weaker immunostaining for iNampt
was seen in WT+STZ mice compared with WT+Saline mice, while stronger
immunostaining was seen in TG+STZ mice compared with TG+Saline mice (Fig. 5g).
Similarly, in CKO mice, NMN concentrations were lower in Cont+STZ and CKO+Sal mice
than in Cont+Sal mice, and lower still in CKO+STZ mice (Supplementary Fig. 6g).
Immunostaining for iNampt was weaker in Cont+STZ and CKO+Sal mice than in Cont+Sal
mice, and weaker still in CKO+STZ mice (Supplementary Fig. 6h). These results suggested
that iNampt levels were affected, at least in part, by glucose or by the Sirt1-determined
tissue NMN concentrations around PT, which regulated Sirt1 and Claudin-1 expression
levels in podocytes.
To confirm a role for NMN in the progression of diabetes-induced albuminuria, we
examined the effects of FK866, an inhibitor of iNampt. FK866 at the dose of 30 mg kg−1
decreased NMN concentrations (Supplementary Fig. 7a), leading to higher levels of
Claudin-1 expression (Supplementary Fig. 7b) and albuminuria (Supplementary Fig. 7c).
EM revealed that FK866 induced higher tight slit pore density and Claudin-1 levels in
podocytes (Supplementary Fig. 7d,e).
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Our data implied a pivotal role for the molecular interplay between iNampt/NMN in PT and
Sirt1/Claudin-1 in podocytes in diabetes-induced albuminuria. We investigated retrograde
interplay from tubular cells to podocytes in an in vivo system. N-methylanthraniloyl (Mant)-
NMN is an autoimaging substance that cannot be synthesized endogenously40,41. One hour
after injection into the renal artery Mant-NMN accumulated in tubules, and 2 h after
injection its accumulation could be detected in glomeruli (Fig. 5h). These temporal changes
in the localization of Mant-NMN strongly suggested that NMN was taken up by tubular
cells and thereafter delivered into glomeruli. In CKO mice that lack the ability to supply
NMN to glomeruli from proximal tubules, the late peak in podocytes was almost abolished
(Fig. 5i). This result supported the hypothesis that the NMN accumulation in podocytes was
derived from proximal tubules and not from slow accumulation in glomeruli. However, we
need to further investigate the detailed mechanisms underlying NMN secretion or
absorption. Presumably, NMN absorption in podocytes will depend on nucleotide receptors
such as P2X or P2Y42.
Sirt1 and Claudin-1 expression in human renal biopsy samples
We evaluated renal the expression of Sirt1 and Claudin-1 in human specimens from 11
subjects with diabetes (Supplementary Table 3). Sirt1 expression in both PT and glomerular
regions was lower, and Claudin-1 expression in the glomerular region was higher, in the
kidneys of subjects with heavy proteinuria (12 g d−1) compared with those with moderate
proteinuria (1.5 g d−1) (Fig. 6a). Claudin-1 expression was negatively correlated with Sirt1
expression in both PT and glomerular regions (Fig. 6b).
Among several clinical parameters, only proteinuria was correlated with both PT and
glomerular Sirt1 immunostaining, and also with glomerular Claudin-1 immunostaining (Fig.
6c). There were no correlations between eGFR and immunostaining patterns for either
protein (Fig. 6d).
DISCUSSION
Our data revealed that reduced Sirt1 expression in PT led to reduced Sirt1 levels and higher
Claudin-1 levels in glomeruli, leading to the initiation of albuminuria in diabetic model
mice. These findings indicated a protective role for PT Sirt1 against albuminuria that is
specific for diabetes-induced albuminuria.
We also showed direct epigenetic regulation of Claudin-1 gene expression by Sirt1. The
significant role of Dnmt1 in Sirt1-induced gene methylation in the present study is
consistent with a recent study showing that Sirt1 directly deacetylated and activated
Dnmt143. The results in our PT-specific gene engineered mice implied that the molecular
changes in PT induced the phenotype changes in glomeruli and podocytes.
We also showed a role for NMN as a candidate mediator of the interplay between PT cells
and podocytes. This retrograde interplay was confirmed by tracing photoactivated labeled
NMN both in vitro and in vivo. Our data suggest that NMN derived from PT cells is
absorbed by podocytes; however, more work is needed to confirm this hypothesis
(Supplementary Fig. 8).
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Finally, we showed that expression of Sirt1 and Claudin-1 was correlated with levels of
proteinuria in human renal biopsy samples from subjects with diabetes. Because neither of
our diabetic mouse models developed significant diabetic nephropathy, we should interpret
the present data carefully. In addition, the mechanisms regulating NMN concentrations in
PT based on glucose condition or Sirt1 expression level remain unclear. However, because
the clinical data are consistent with the results obtained from mouse models, we suggest that
initial downregulation of Sirt1 expression in PT, followed by downregulation of Sirt1 and
upregulation of Claudin-1 in glomeruli, has a role in the initial changes in diabetes-induced
albuminuria44. The results of this study could contribute to novel therapeutic strategies to
prevent diabetes-induced albuminuria.
METHODS
Production of Sirt1-TG mice (TG mice) and kidney-specific Sirt1 knockout mice (CKO
mice)
To prepare renal tubule-specific Sirt1 TG mice on a C57BL/6J background, a transgenic
expression vector containing a mouse sodium phosphate cotransporter IIa (Npt2) promoter
and human Sirt1 cDNA tagged with an 8-amino acid FLAG epitope was constructed as
described previously14. Immunostaining using an antibody to FLAG showed expression of
the transgene in PT but not in glomeruli (Supplementary Fig. 1c). Mice were propagated as
heterozygous transgenic mice by breeding them with WT C57BL/6 mice. F2 mice were used
as TG mice, and age- and sex-matched littermates were used as wild-type control (WT)
mice. Kidney-specific Sirt1 knockout (Sirt1−/−) mice (CKO mice) were produced by
crossing Sirt1flox/flox mice on a C57BL/6J background with γGT-Cre mice (Jackson
Laboratory)45. γGT-Cre transgenic mice on a C57BL/6J background have demonstrated PT-
specific Cre recombinase activity2. Therefore, Sirt1flox/flox/γGT-Cretg/+ (PT-specific
Sirt1−/−) mice had a specific deletion of Sirt1 in PTs. The following three types of control
mice were produced by this breeding: Sirt1flox/flox, Sirt1+/+/γGT-Cretg/+, and Sirt1+/+. In the
following studies, Sirt1flox/flox/γGT-Cretg/+ were crossed with Sirt1flox/flox to produce
Sirt1flox/flox/γGT-Cretg/+ (PT-specific Sirt1−/−) mice. Sirt1flox/flox mice were used as control
(Cont) mice. All animal studies were performed in accordance with the animal
experimentation guidelines of Keio University School of Medicine.
Podocyte-specific Claudin-1 overexpression in mice
Mouse Claudin-1 cDNA was cloned as described previously46. The cDNA was inserted
downstream of a podoyte-specific promoter, a 2.5-kb fragment of the human NPHS2
(Podocin) promoter47. Eight-week-old male mice were treated with saline or STZ. One
week after saline or STZ injection, 50 µg of 2.5 AU hemagglutination virus of Japan (HVJ)-
envelope vector (GenomeONE-Neo, Ishihara Sangyo, Osaka, Japan) that carried plasmid
DNA was injected into the tail vein in 120 µl of suspension buffer weekly. Mice were killed
24 weeks after injection.
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Experimental protocol for animal experiments
STZ treatment—Eight-week-old male mice were treated with streptozotocin (STZ, Sigma-
Aldrich, St. Louis, MO) dissolved in 100 mmol l−1 citrate buffer, pH 4.5, or with phosphate-
buffered saline (PBS) dissolved in citrate buffer.
db/db mice—To produce compound mutant mice with a Sirt TG db/db genotype, PT-
specific Sirt1 TG (TG) mice were bred with male mice heterozygous for the db mutation
(db/m). Both the Sirt1 TG and db heterozygous breeders were on a C57BL/6J genetic
background. Offspring from the F1 generation, which were heterozygous for the db
mutation and also expressed the Sirt1 transgene, were then bred with mice heterozygous for
the db mutation. The F2 generation contained the desired compound mutant (Sirt-Tg, db/db)
and the other genotypes used. The following four genotypes were used: 1) wild-type
nontransgenic (WT)-nondiabetic (ND); 2) WT-db/db; 3) TG-ND; and 4) TG-db/db. At the
age of 6 months, mice were sacrificed.
5/6 Nephrectomy—Eight-week-old male C57BL/6 mice were subjected to 5/6
nephrectomy in two stages29. In the first stage, the left kidney was decapsulated, and then
the upper and lower poles were partially resected via a left flank incision. After one week,
the entire right kidney was removed5. Sham operated mice were used as controls. Twenty-
four weeks after the surgery, kidney tissues were harvested.
FK866 treatment—FK866 (Sigma, St Louis, MO) was dissolved in dimethyl sulfoxide
and 25 mg ml−1 aliquots were stored at −80 °C until further use. Male C57BL/6 mice
received intraperitoneal injections of 30 mg kg−1 FK866 further diluted in PBS twice a day
3 d a week from 8 weeks to 32 weeks of age.
Histopathological examination—PAS-stained samples from 30 consecutive glomeruli
per animal were examined. The glomerular area was traced along the outline of the capillary
loop using Image-Pro Plus 3.0 (Media Cybernetics, Silver Spring, MD). The extent of the
mesangial matrix was determined by assessment of the PAS-positive and nucleus-free areas
in the mesangium. Immunohistochemistry was performed as previously described14. Briefly,
paraffin sections (4 µm) were fixed in 3% formaldehyde and stained using primary
antibodies against FLAG (Sigma), Sirt1 (Millipore, Bedford, MA), Claudin-1 (Invitrogen,
San Diego, CA). The sections were stained with biotin-labeled goat anti-rabbit IgG (Vector)
or biotin-labeled anti-mouse IgG (Vector) and then treated with the Vectastain Elite ABC
Kit (Vector).
Immunofluorescence staining—Indirect immunofluorescence staining for Sirt1 was
carried out on frozen kidney sections using rabbit monoclonal anti-Sirt1 antibody (Cell
Signaling Technology). Alexa Fluor goat anti-rabbit IgG (Molecular Probes, Eugene, OR,
USA) was used as the secondary antibody. As a negative control, the primary antibody was
replaced with nonimmune serum from the same species; no staining occurred.
Immunofluorescence staining for AQP1 was performed in a similar manner using respective
antibodies. For fluorescence microscopy, all sections were stained and analyzed at the same
time to exclude artifacts due to variable decay of the fluorochrome. Sections were examined
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using a Nikon Microphot-FX fluorescence microscope equipped with a Spot II digital
camera.
Electron microscopy—For electron microscopy evaluation, kidney tissue was embedded
in Epon epoxy resin (Miller-Stephenson Chemical Company, Sylmar, CA)48. Electron
micrographs of 10 glomeruli per kidney were randomly taken for each mouse to evaluate
podocyte morphometry. Photomicrographs of the GBM were analyzed for the density of
tight slit pores between the podocyte foot processes according to published methods6. Tight
slit pores were identified by the obliteration of spaces between adjacent foot processes. The
numbers of tight slit pores were counted and divided by the GBM length (mm) to determine
the density of tight slit pores. A total of 500 foot processes from each group were evaluated
for the analysis of slit pore density.
Immunogold electron microscopy—Mouse kidneys from the four groups were finely
chopped, fixed in 4% paraformaldehyde and 0.2% picric acid, and embedded in LR white
resin. Ultrathin sections were blocked with goat IgG and incubated with rabbit anti-
Claudin-1 (Invitrogen) followed by 15 nm colloidal gold-conjugated goat anti-rabbit IgG
(EBS, East Granby, CT). Grids were counterstained with 0.5% osmium and 1% uranyl
acetate, and bound gold particles were visualized and photographed by electron microscopy.
The numbers of gold particles µm−2 were then counted using Scion software, and averages
were compared statistically.
Laser microdissection—Laser microdissection was performed according to previous
reports49,50. We used poly-L-lysine to prevent PECs (kindly provided by Professor Stuart J.
Shankland and Cheri Campbell, Division of Nephrology, University of Washington) from
detaching from glass slides and a modified PAS staining protocol specific for laser
microdissection samples from cryosections, not generally used on paraffin-embedded
samples. Freshly frozen kidney tissue was cut into 7-µm-thick sections. Cryosections were
mounted onto a polyethylene membrane previously attached to a glass slide that had been
coated with 0.1% poly-L-lysine (Sigma-Aldrich). The sections were stained with PAS,
counterstained with hematoxylin, and stored at −80 °C until use. These tissues were excised
using a PALM MicroBeam IP 230V Z microscope for laser pressure catapulting (P.A.L.M.
Microlaser Technologies, Bernried Germany) as described previously50. RNA from
microdissected tissue was prepared using the PALM RNA extraction kit.
Microarray Analysis—Mice in the WT+STZ and TG+STZ groups were killed at 32
weeks of age. Before microarray analysis, we dissected the glomerular regions. Micro-
dissected glomeruli were immediately used for total RNA isolation and subjected to analysis
on Affymetrix Mouse Genome 430 2.0 microarray chips according to Affymetrix standard
protocols (http://www.affymetrix.com). Genes were excluded if the signal strength did not
significantly exceed background values and if expression did not reach a threshold value for
reliable detection (P < 0.05) in each of the 3 separate studies. Finally, genes were excluded
if the level of expression did not vary by more than 4-fold or less than 0.25-fold between
WT+STZ and Tg+STZ. The remaining genes were subjected to nonparametric Welch t-tests
and are reported with their respective fold changes and P-values.
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Culture of podocytes and HK-2 cells—Conditionally immortalized mouse podocytes
were donated by P. Mundel (Mt. Sinai School of Medicine, New York, NY, USA) and K.
Asanuma (Juntendo University, Tokyo, Japan)51. Mouse Claudin-1 cDNA was cloned as
described previously46. In conditioned medium experiments, control or Sirt1 vector
transfected HK2 cells seeded at a density of 5 × 105 100 mm−2 were cultured for 24 h with
either normal glucose (5 mM, NG) or high glucose (25 mM, HG). The conditioned medium
from each treatment was then transferred onto culture plates containing podocytes. DMEM
containing 10% FBS was used for both cell types. Podocytes were seeded at a density of 5 ×
105 100 mm−2, incubated for 7 d (differentiation) and used for experiments. Differentiation
of cells was confirmed as previously described51. The NAD+/NADH ratio was measured in
whole cell extracts of HK2 cells or podocytes using the BioVision NAD/NADH
Quantitation Kit (BioVision, Mountain View, CA). NMN was detected by high-performance
liquid chromatography (HPLC) as previously described39.
Culture of HRE cells—Primary HRE cells (Clonetics, San Diego, CA) were cultured
according to the manufacturer’s instruction. The expression plasmid containing human Sirt1
cDNA (pcDNA3.1-Sirt1) and the control plasmid (pcDNA3.1) were transfected into HRE
cells using Lipofectamine 2000 (Invitrogen). For treatment with 5-Aza-dC (Sigma-Aldrich),
the cells were treated with 5 µM 5-aza-dC for 96 h. For Dnmt siRNA treatment, Dnmt
siRNA duplex was purchased from Sigma-Aldrich. The sense sequences were 5′-[dT]
GGAAUGGCAGAUGCCAACAGC [dT]-3′ for Dnmt1, 5′-[dT]
GAAAGCGAAGGUCAUUGCA [dT]-3′ for Dnmt3a, and 5′-[dT]
GCUAGCGAAGGUCAUUGCA [dT]-3′ for Dnmt3b. Control siRNA consisted of a
scrambled siRNA construct encoding a nonspecific siRNA without mammalian homology.
These siRNAs (100 pmol µl−1) were transfected using Lipofectamine 2000 (Invitrogen) for
24 h.
RNA isolation, reverse transcription, and quantitative PCR—Real-time PCR was
performed using the ABI Prism 7700 sequence detection system (Applied Biosystems,
Foster City, CA) and the SYBR GREEN system (Applied Biosystems)13,14. The sequences
of the primers are listed in Supplementary Table 5. The relative mRNA levels for the
specific genes were normalized to the level of mRNA expression for the housekeeping gene
GAPDH.
Immunoblotting—Immunoblotting was performed as described previously13,14 using
specific antibodies against Sirt1 (Millipore) and Claudin-1 (Invitrogen). For assaying β-
catenin/Snail signaling, an anti-Synaptopodin primary antibody (Sigma, St Louis, MO;
Biodesign, Sabo, ME), anti-β-catenin antibody (catalog number 610154; BD Transduction
Laboratories, San Jose, California), and anti-Snail antibody (ab17732; Abcam) were used.
The β-actin band recognized by a specific antibody (Sigma) was used as a loading control.
Band intensities were quantified using Scion Image Software (Scion Corp, Frederick, MD).
Claudin-1 CpG methylation in vivo by methylation-specific PCR (MSP) and
real-time methylation-specific PCR (real-time MSP)—Total genomic DNA from the
kidneys or HRE cells was extracted using a DNeasy Kit (Qiagen Japan, Tokyo). Bisulfite
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conversion of genomic DNA was performed using a Zymo EZ DNA Methylation Gold™ kit
(Zymo Research Corp., Orange, CA). MSP was performed to determine the methylation
status of the Claudin-1 gene, and real-time MSP was performed for quantitative analysis of
the methylation of the Claudin-1 gene as described previously11. Specific methylated or
unmethylated sequences of primer sets are listed in Supplementary Table 6. Two
independent bisulfite modifications were performed, and five independent MSPs and real-
time MSPs were performed. Representative bands of MSP are shown in the figures52.
Bisulfite genomic sequencing—DNA was extracted from cells according to standard
procedures. A 2-µg quantity of DNA was then bisulfite treated using the EpiTect Bisulfite
Kit (Qiagen) and amplified via nested PCR using the following PCR primers. PCR1
forward: 5′-AGTTGTATAGAGAGTAAGGGTATAGGT-3′, reverse: 5′-
TTAACCTAAAACTTAAATTCTTTCTAC-3′, PCR2 forward: 5′-AGGTATTAATT
TGTTTGTAGAGATT-3′, reverse: 5′-TAACCTCTAAACTAAATAAAACTACTACA-3′.
PCR products were cloned using the TOPO TA cloning kit (Invitrogen). Ten random clones
were sequenced using an ABI3730 DNA analyzer (Applied Biosystems) with the following
sequence primers; forward: 5′-CAGGAAACAGCTATGAC-3′, reverse: 5′-
GTTTTCCCAGTCACGACGT-3′.
Sirt1 small interfering RNA (siRNA) experiments—The siRNA for Sirt1 was
prepared by Japan Bio Service (JBios, Saitama, Japan). The targeted sequence to silence the
transcription of Sirt1 was 5′-GAAGTTGACCTCCTCATTG-3′. An siRNA targeting
sequence for green fluorescent protein (GFP; 5′-GGCTACGTCCAGCAGCGCACC-3′)
mRNA was used as a negative control. As another negative control, a scrambled siRNA
(JBioS) that did not exhibit homology to any coding region was used. The sequence: 5′-
TCCGAACGTGGCACGA-3′ was used as the scrambled siRNA control.
Chromatin Immunoprecipitation (ChIP) assay—HRE cells were treated with or
without the Sirt1 inhibitor sirtinol (20 µM, 48 h, Sigma-Aldrich) for 48 h and used for the
following ChIP assay. The ChIP assay was performed with 1 × 106 HRE cells per assay
using the ChIP assay kit (Upstate Biotechnology Inc., Lake Placid, NY) as described by the
manufacturer’s protocol. All antibodies used in this study were purchased from Abcam.
Antibodies against acetylated histone H3, acetylated histone H4, dimethylated H3K9,
dimethylated H3K27, and dimethylated H4K20 were used for immunoprecipitation (IP), and
rabbit IgG was used as a negative control to check the specificity of IP. After IP, recovered
chromatin samples were subjected to PCR with the following set of primers:
AACTCTCCGCCTTCTGCAC and ACACGCAGGACATCCACAG for the CpG region of
Claudin-1 and CCGTTGGCATGAAGTGT ATG and AAGGCAGAGAGAAGCAGCAG
for the non-CpG region of Claudin-1. The PCR products were run on agarose gels. The
results from three independent experiments are presented.
Quantification of NMN autofluorescence by photoactivatable NMN—Intracellular
endogenous NMN autofluorescence was monitored by confocal microscopy as described
previously39 with slight modification. Briefly, 100 ml of 1 N HClO4 was added to cells or
kidney sections on a culture dish or a glass plate. Then, these sections were embedded with
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1 N KOH and, after 5 min, an additional 100 ml of 0.1 M bicine pH 7.4 was added, followed
by 1 N KOH and acetophenone. These samples were incubated for 15 min, and then 100 ml
formic acid was added. By means of this derivatization procedure, NMN shows fluorescence
with peaks of excitation and emission in the regions of 332 nm and 454 nm, respectively. A
confocal microscope equipped with a custom 340 ± 10 nm excitation and 460 ± 25 nm
emission filter set was used together with a Zeiss Axiocam digital camera (Carl Zeiss) for
imaging intrinsic NMN autofluorescence from HK2 cells, podocytes, or kidney sections
freshly isolated from each mouse. Collected images were subsequently analyzed using Zeiss
Axiovision 4.4 software. Background fluorescence intensity was subtracted from each data
point.
Synthesis of Mant-NMN and intra-renal artery injection of Mant NMN—To
elucidate whether NMN is released from PTs and then mobilized into podocytes,
fluorescence-labeled exogenous NMN was injected into mice. We used Mant (N-
methylanthraniloyl) for labeling NMN. Mant-NMN was synthesized as described39,40.
Saline or Mant-NMN (500 mg kg−1 body weight) was administered by intra-arterial
injection into 8-week-old male mice as described41. Thereafter, kidney samples were
harvested 1, 2, and 4 h after NMN injection, and tissues were examined by confocal
microscopy using an LSM 510 Zeiss microscope. Fluorescence was detected at 430–480 nm
with excitation at 364 nm to detect the signal of Mant. To confirm whether positive signals
of Mant-NMN conformed with PTs or podocytes, sequential sections were used for
immunofluorescence staining of kidney sections. The primary antibodies used for
immunofluorescence studies were anti-AQP1 (a PT marker) (Santa Cruz Biotechnology)
and anti-podocin (a podocyte marker) (Sigma-Aldrich).
Human renal specimens from needle biopsy—Needle renal biopsy specimens were
obtained from 11 subjects with diabetic nephropathy. No subjects received steroids or
immunosuppressive drugs before renal biopsy. As controls, pre-transplant biopsies from five
living donors were obtained. Clinical data from the subjects were documented at the time of
renal biopsy and are summarized in Supplementary Table 3. The value of eGFR was
calculated with a revised MDRD equation for the Japanese population: eGFR (ml min−1
1.73 m−2). Human kidney samples were collected from renal biopsies at Japanese Red Cross
Shizuoka Hospital. Written informed consent was obtained from all participants. The study
was performed in accordance with the declaration of Helsinki, and the study protocol was
approved by the Human Ethics Review Committee of Japanese Red Cross Shizuoka
Hospital. Immunohistochemistry for Sirt1 or Claudin-1 was performed on each human
sample essentially as described previously. Results are reported as the labeling index, which
represents the percentage of total glomerular tuft area that was stained.
Statistical analysis—Data are expressed as means ± s.e.m. Data were analyzed using
one- or two-way analysis of variance, as appropriate, followed by Bonferroni's multiple
comparison post hoc test. P values < 0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Alleviation of albuminuria in diabetes-induced albuminuria in transgenic (TG) mice with
proximal tubule (PT)-specific Sirt1 overexpression. (a,b) Temporal changes in Sirt1
expression 0, 8, and 24 weeks after streptozotocin (STZ) treatment in wild-type (WT) mice.
(a) Immunostaining for Sirt1 in the kidney. The scale bar represents 50 µm. (b) Sirt1 mRNA
expression levels normalized to that of GAPDH in PT and glomeruli of saline- or STZ-
treated mice. (c) Immunoblotting (left) and immunostaining (right) for Sirt1 expression in
the kidneys of TG and WT mice treated with saline (Sal) or STZ at 24 weeks after STZ
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treatment. Sirt1 band in TG mice consisted of a band for endogenous mouse Sirt1 (100 kDa)
and one for FLAG-tagged overexpressed human Sirt1 (101 kDa). Band intensity was
normalized to that for β-actin. Scale bar, 50 µm. (d) Urinary albumin excretions at 8 weeks
(left) and 24 weeks (right) after STZ treatment. (e) Representative electron
photomicrographs 8 weeks (left) and 24 weeks (right) after STZ treatment. Bar graphs
represent the tight slit pore densities. Scale bar, 500 nm. (f) The mRNA levels for Claudin-1.
(g) Immunostaining for Claudin-1. Arrows indicate stained PECs. Triangles indicate stained
cells in the glomeruli. Bars, 50 µm. (h,i) The expression of Sirt1 (left) and Claudin-1 (right)
mRNA in micro-dissected parietal epithelial cells (PECs) and proximal tubules (PT) of WT
mice (h) and TG mice (i) treated with saline or STZ. **P < 0.01, *P < 0.05, n = 8.
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Figure 2.
Direct effects of Claudin-1 on podocytes, mice with streptozotocin-induced diabetes, and the
phenotypes of proximal tubule (PT)-specific Sirt1 knockout mice. (a) Claudin-1 staining
after intravenous injection of NPHS2-Claudin-1 (Cldn-1) or control vector (Cont) into saline
(Sal)-treated or streptozotocin (STZ)-treated mice. The right panel shows mRNA expression
for Claudin-1. Scale bar, 50 µm. (b) Albuminuria in Cont+Sal, Cldn-1+Sal, Cont+STZ and
Cldn-1+STZ mice. (c) Electron photomicrographs of kidneys from mice in each
experimental group. The bar graph shows tight slit pore densities. Scale bar, 500 nm. (d)
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Expression levels for Claudin-1, β-catenin, Snail, Synaptopodin, and Podocin mRNAs in
micro-dissected glomeruli in all four groups of mice. (e) Immunoblotting analysis for the
expression of Claudin-1, β–catenin, Snail, and Synaptopodin in cultured podocytes
transfected with expression vectors for Claudin-1, Claudin-2, Claudin-4 or empty vector
pcDNA3. (f) Production of PT-specific Sirt1−/− (conditional knockout, CKO) mice.
Immunoblotting analysis for Sirt1 expression in the heart, lung, liver, and kidney of CKO
and control (Cont) mice. (g) Expression of Sirt1 in PTs (left) and glomeruli (right) of CKO
and Cont mice (h) Electron photomicrographs of a kidney in STZ-treated CKO and control
mice. The bar graph shows quantification of tight slit pore densities. Scale bar, 500 nm. (i)
Immunostaining for Claudin-1 in kidneys (left) and mRNA expression for Claudin-1 in
micro-dissected glomeruli (right) from Cont+Sal, Cont+STZ, CKO+Sal and CKO+Sal mice.
Scale bar, 50 µm. (j) Albuminuria in each experimental group. *P < 0.05, n = 8.
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Figure 3.
Proximal tubule-specific Sirt1 overexpression alleviates diabetic albuminuria in db/db mice
but not in 5/6th nephrectomized (5/6Nx) mice. (a) Immunoblotting for Sirt1 in the kidneys
of TG mice and wild-type littermates (WT) crossed with db/db or non-diabetic mice (ND).
The lower panel shows the results of densitometry analysis of band intensity. (b)
Albuminuria in WT-ND, TG-ND, WT-db/db and TG-db/db mice. (c) Immunostaining for
Claudin-1 in kidneys from each experimental group. The lower panel shows mRNA
expression for Claudin-1. Scale bar, 50 µm. (d) Electron photomicrographs of a kidney from
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each mice group (left). The bar graph (right) shows the tight slit pore densities. Scale bar,
500 nm. (e) Immunoblotting for Sirt1 in the kidneys of TG and WT mice after 5/6Nx or
sham operation. The lower panel shows densitometry analysis of band intensity. (f)
Albuminuria in TG and WT mice after 5/6Nx or sham operation. *P < 0.05, n = 8.
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Figure 4.
Epigenetic regulation of Claudin-1 gene expression by Sirt1. (a) Effects of glucose
concentration on the expression of Sirt1 (left) and Claudin-1 (right). (b) Effects of Sirt1
overexpression (left) and combined effects of glucose and Sirt1 (right) on Claudin-1
expression. (c) CpG islands and positions of primers for methylated (MF and MR) and
unmethylated (UMF and UMR) genes on the Claudin-1 gene of mice (left) and human
(right). (d) Effects of glucose concentration (left) and Sirt1 overexpression (right) on
Claudin-1 gene methylation. (e) Effects of transfection with siRNA for Sirt1 on Claudin-1
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gene methylation (left) and Claudin-1 protein expression (right). (f) Combined effects of
glucose and Sirt1 on Claudin-1 gene methylation. (g) Methylation of Claudin-1 gene (left)
and the level of Claudin-1 protein (right) after treatment with the DNA methyltransferase
(Dnmt) inhibitor 5-aza-dC. (h) Methylation of the Claudin-1 gene with or without
transfection with Sirt1 expression vectors or Dnmt1 siRNA. (i) ChIP assays using HRE cells
cultured with sirtinol (S, 20 mM) or vehicle (C). Antibodies against acetylated histone 4
(AcH4), acetylated histone 3 (AcH3), dimethylated H4K20 (Me2H4K20), and dimethylated
H3K9 (Me2H3K9) were used. (j) Claudin-1 CpG methylation in the kidneys of TG mice
treated with or without streptozotocin (STZ). Left; Methylation-specific PCR and real-time
methylation-specific PCR using micro-dissected PECs. Right; Claudin-1 mRNA expression
in PECs. (d,e,f,g,h,j) M indicates methylated DNA and U unmethylated DNA. *P < 0.05, n
= 5.
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Figure 5.
Evidence for the retrograde interplay from tubular cells to podocytes. (a) HK-2 cells were
cultured under the four conditions of NG (normal glucose)+Cont (control vector), NG+Sirt1
(Sirt1 expression vector), HG (high glucose)+Cont and HG+Sirt1. Immunoblotting for Sirt1
(upper) and densitometry analysis (lower). (b) Sirt1 (upper) and Claudin-1 (lower)
expression in podocytes cultured in conditioned medium (CM) from each of the above four
experimental conditions or in NG or HG conditions without CM. (c) NMN concentrations
(upper) and NAD/NADH ratio (lower) of each CM. (d) Sirt1 (upper) and Claudin-1 (lower)
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expression in podocytes cultured in each CM supplemented with NMN, phosphate-buffered
saline (PBS), or sirtinol. (e) Intracellular autofluorescence of NMN in HK-2 cells (upper)
and podocytes (lower) at 0, 1, and 2 h after CM transfer. CM were from the four conditions
of HK-2 cell culture media. Scale bar, 20 µm. (f,g) Tissue NMN concentrations (f) and
iNAMPT immunostaining (g) of kidneys from proximal tubule-specific Sirt1 transgenic
(TG) mice and wild-type littermates (WT) mice 24 weeks after treatment with saline (Sal) or
streptozotocin (STZ). Scale bar, 50 µm. (h,i) Representative confocal images for Mant
fluorescence in normal (h) and PT-specific Sirt1-deficient mice (i). Mant-NMN (green, left)
was detected at 0, 1, 2, 4 h after injection. Sequential sections were stained with anti-AQP-1
antibody (h,i; right). Glomeruli are indicated in circles. Temporal profiles of the mean Mant-
NMN intensity in tubular and podocyte regions are shown in the graph, n = 5. *P < 0.05, n =
5. Scale bar, 50 µm.
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Figure 6.
Glomerular Sirt1 or Claudin-1 immunostaining in human renal biopsy specimens. (a)
Representative photomicrograph of HE staining or immunostaining for Sirt1 and Claudin-1
in needle renal biopsy specimens of subjects with diabetic nephropathy (DN) (sample
names: DN-3 and 6, Supplementary Table 3) and a control (sample name: CO-1). Bars; 50
nm. (b) The relationship between immunostaining for Claudin-1 and that for Sirt1 in the
proximal tubular region (upper) and glomerular region (lower) in renal biopsy specimens
from subjects with DN, n = 11. (c) The relationships between proteinuria and
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immunostaining for proximal tubular Sirt1 (left), glomerular Sirt1 (middle), and Claudin-1
(right), n = 11. (d) The relationships between eGFR and immunostaining for proximal
tubular Sirt1 (left), glomerular Sirt1 (middle) and Claudin-1 (right), n = 11.
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